Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) (O3NPIQ)
Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)
Sponsor: Bernardino Clavo, MD, PhD
Listed as NCT04299893, this PHASE2/PHASE3 trial focuses on Chemotherapy-induced Peripheral Neuropathy and Pain Syndrome and remains actively recruiting participants. Sponsored by Bernardino Clavo, MD, PhD, it has been updated 11 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 6 earlier versions
-
Dec 2022 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Dec 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Apr 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bernardino Clavo, MD, PhD
- Fundación DISA, Spain
- Fundación Española del Dolor (FED)
- Instituto de Salud Carlos III
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas
- Servicio Canario de Salud
For direct contact, visit the study record on ClinicalTrials.gov .